Use of Global Visual Acuity Data in a Time Trade-off Approach to Calculate the Cost Utility of Cataract Surgery

被引:35
作者
Lansingh, Van C. [2 ,3 ]
Carter, Marissa J. [1 ]
机构
[1] Strateg Solut Inc, Cody, WY 82414 USA
[2] Fdn Hugo Nano, Buenos Aires, DF, Argentina
[3] Fdn Vis, Asuncion, Paraguay
关键词
WILLINGNESS-TO-PAY; EYE CARE PROGRAM; INTRAOCULAR-LENS; UNITED-STATES; OUTCOMES; HEALTH; PHACOEMULSIFICATION; EXTRACTION; QUALITY; LIFE;
D O I
10.1001/archophthalmol.2009.113
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To determine the cost utility of cataract surgery worldwide using visual acuity (VA) outcomes and utility values determined by the time trade-off (TTO) method. Data Sources: Some cost data were taken from a previous search conducted for 1995 to 2006 and we searched MEDLINE and Scopus and Google for more recent data (2006 and 2007). Study Selection: Articles were identified from the literature using "cataract surgery" in combination with the terms outcome or visual acuity. Additional searches were conducted using individual countries as a term in combination with VA, outcome, or cost. Regression curves were constructed from utility values derived from a TTO study and VA data. Gains in quality-adjusted life-years (QALYs) were calculated based on life expectancy tables from the World Health Organization and discounts of 3% for both cost and benefit. Sensitivity analyses explored the effect of changes in discounting, life expectancy, preoperative VA, and cost. Data Extraction: If the data were usable, they were kept; otherwise they were discarded. Data Synthesis: Preoperative VA (logMAR) correlated with increasing gross national income per capita (Pearson correlation coefficient, -0.784; P<.001) and showed that in developing countries preoperative vision is much poorer compared with developed countries. Cost utility data ranged from $3.5 to $834/QALY in developing countries to $159 to $1356/QALY in developed countries. Sensitivity analysis showed that changing life expectancy, VA, and discount rate resulted in moderate changes. Conclusions: The TTO approach demonstrates that cataract surgery is extremely cost-effective.
引用
收藏
页码:1183 / 1193
页数:11
相关论文
共 91 条
  • [1] Economic costs of cataract surgery using a rigid and a foldable intraocular lens
    Afsar, AJ
    Woods, RL
    Patel, S
    Rogan, F
    Wykes, W
    [J]. OPHTHALMIC AND PHYSIOLOGICAL OPTICS, 2001, 21 (04) : 262 - 267
  • [2] Audit of outcome of an extracapsular cataract extraction and posterior chamber intraocular lens training course
    Alhassan, MB
    Kyari, F
    Achi, IB
    Ozemela, CP
    Abiose, A
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2000, 84 (08) : 848 - 851
  • [3] Willingness to pay to shorten waiting time for cataract surgery
    Anderson, G
    Black, C
    Dunn, E
    Alonso, J
    ChristianNorregard, J
    FolmerAnderson, T
    BernthPeterson, P
    [J]. HEALTH AFFAIRS, 1997, 16 (05) : 181 - 190
  • [4] [Anonymous], COST EFF THRESH
  • [5] The value of DALY life: problems with ethics and validity of disability adjusted life years
    Arnesen, T
    Nord, E
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1999, 319 (7222): : 1423 - 1425
  • [6] Cost effectiveness of cataract surgery - A comparison of conventional extracapsular surgery and phacoemulsification at Flinders Medical Centre
    Asimakis, P
    Coster, DJ
    Lewis, DJ
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF OPHTHALMOLOGY, 1996, 24 (04): : 319 - 325
  • [7] Feasibility, validity and test-retest reliability of scaling methods for health states: The visual analogue scale and the time trade-off
    Badia, X
    Monserrat, S
    Roset, M
    Herdman, M
    [J]. QUALITY OF LIFE RESEARCH, 1999, 8 (04) : 303 - 310
  • [8] Balent LC, 2001, OPHTHALMIC SURG LAS, V32, P446
  • [9] Cataract surgical coverage and outcome in the Tibet Autonomous Region of China
    Bassett, KL
    Noertjojo, K
    Liu, L
    Wang, FS
    Tenzing, C
    Wilkie, A
    Santangelo, M
    Courtright, P
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2005, 89 (01) : 5 - 9
  • [10] Discounting health effects in pharmacoeconomic evaluations: Current controversies
    Bos, JM
    Postma, MJ
    Annemans, L
    [J]. PHARMACOECONOMICS, 2005, 23 (07) : 639 - 649